Comprehensive medication guide to Flurazepam including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$30 copay for generic flurazepam on most commercial plans (Tier 1–2 preferred generic); Medicare Part D typically $0–$15 after deductible; some plans may impose quantity limits for Schedule IV controlled substances.
Estimated Cash Pricing
$585–$608 retail for a 30-day supply of 30 mg capsules; as low as $144 with a GoodRx coupon (approximately 76% off retail). SingleCare typically shows around $492 for the same quantity.
Medfinder Findability Score
42/100
Summarize with AI
On this page
Flurazepam is a long-acting benzodiazepine hypnotic approved by the FDA for the short-term treatment of mild to moderate insomnia. Originally marketed as Dalmane by Roche Pharmaceuticals starting in 1968, it was one of the first benzodiazepine sleep medications brought to market. The brand name Dalmane has since been discontinued, and only generic flurazepam hydrochloride is available today.
Flurazepam is indicated for patients with difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakening. It comes as oral capsules in 15 mg and 30 mg strengths, taken at bedtime. The standard adult dose is 30 mg; elderly or debilitated patients are typically started at 15 mg to reduce the risk of falls and over-sedation.
As a DEA Schedule IV controlled substance, flurazepam carries a risk of abuse, physical dependence, and withdrawal. The FDA requires a Boxed Warning for all benzodiazepines covering the risks of combined use with opioids, and the risks of addiction and withdrawal reactions. Flurazepam is not approved for patients under 18 years of age and is contraindicated in pregnancy.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Flurazepam works by binding to the benzodiazepine site on GABA-A receptors in the brain. GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter — when GABA binds to its receptor, it opens a chloride ion channel that reduces neuronal excitability. Flurazepam enhances this inhibitory effect, increasing the influx of chloride ions and producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.
What makes flurazepam distinctive is its extremely long-acting active metabolite: N-desalkylflurazepam, with a half-life of approximately 40–114 hours. This metabolite continues to enhance GABA activity for days after a single dose. With nightly use, levels accumulate over the first week. This long half-life makes flurazepam effective for sleep maintenance insomnia but also accounts for its characteristic next-day sedation and hangover effect.
Flurazepam is metabolized hepatically via the CYP3A4 enzyme pathway. Drugs that inhibit CYP3A4 (such as certain antifungals and HIV medications) can increase flurazepam levels, while CYP3A4 inducers (such as rifampin or carbamazepine) can reduce its effectiveness. Because drug interactions persist for several days after stopping flurazepam due to the long-acting metabolite, patients must be counseled to avoid alcohol and other CNS depressants even after they stop taking the medication.
15 mg — capsule
Starting dose for elderly or debilitated patients; reduces risk of falls and oversedation
30 mg — capsule
Standard adult dose; taken at bedtime; only with a full 7-8 hours available for sleep
Flurazepam is one of the harder-to-find sleep medications in the United States as of 2026. It remains on the ASHP Drug Shortage list (last updated December 16, 2025) with only one active manufacturer: Chartwell Rx, which launched flurazepam capsules in November 2023 after Mylan (Viatris) permanently discontinued both the 15 mg and 30 mg products. Rising Pharmaceuticals has announced plans to enter the market but has not provided a launch timeline.
The single-manufacturer situation means not all pharmacy chains stock Chartwell's flurazepam. Major chains including CVS, Walgreens, and Rite Aid may not carry it at all locations. Independent pharmacies with specialty wholesaler relationships tend to have better access. Patients may need to call ahead, request a special order, or search across multiple pharmacies to fill a prescription. DEA production quotas for Schedule IV controlled substances further constrain the total supply that can be manufactured annually.
If you're having trouble locating flurazepam, medfinder calls pharmacies near you to find which ones have it in stock. You provide your medication, dosage, and location — results are texted to you, so you don't have to spend hours on hold.
As a DEA Schedule IV controlled substance, flurazepam requires a prescription from a licensed healthcare provider with DEA prescribing authority. No specialist-only restriction applies — any provider with appropriate DEA registration can prescribe it. The following provider types routinely prescribe flurazepam for insomnia:
Primary care physicians (PCPs) — family medicine and internal medicine physicians are the most common prescribers
Psychiatrists — for insomnia with a comorbid anxiety or mood disorder component
Sleep medicine specialists — board-certified sleep physicians managing chronic insomnia
Neurologists — for insomnia associated with neurological conditions
Nurse practitioners (NPs) and physician assistants (PAs) — in most states with appropriate DEA registration; state-specific supervision requirements vary
Telehealth prescribing of flurazepam is significantly limited in 2026. The DEA generally requires an in-person evaluation before prescribing Schedule IV benzodiazepines for new patients, and most major telehealth platforms do not prescribe benzodiazepines due to regulatory and liability concerns. Patients needing a new flurazepam prescription will generally need to see a provider in person.
Yes. Flurazepam is a DEA Schedule IV controlled substance. Schedule IV drugs have an accepted medical use in the United States but carry a risk of limited physical or psychological dependence compared to Schedule III drugs. All benzodiazepines — including flurazepam — are Schedule IV.
As a Schedule IV controlled substance, flurazepam requires a valid prescription from a licensed healthcare provider with DEA prescribing authority. Federal law permits up to 5 refills within 6 months of the original prescription date for Schedule IV substances. Many states impose stricter requirements — some limit initial prescriptions to 30-day supplies or require electronic prescribing for all controlled substance orders.
The DEA also sets annual manufacturing quotas for Schedule IV controlled substances, which caps the total amount of flurazepam that can be produced in the United States each year. This is one reason why flurazepam availability is more constrained than non-controlled medications. In September 2020, the FDA updated the Boxed Warning for all benzodiazepines — including flurazepam — to more prominently describe the risks of abuse, misuse, addiction, physical dependence, and life-threatening withdrawal reactions.
The most frequently reported side effects include:
Next-day drowsiness / "hangover effect" (most characteristic side effect)
Dizziness and lightheadedness
Ataxia (unsteadiness/staggering)
Anterograde amnesia (difficulty forming new memories)
Headache
Nausea, heartburn, upset stomach
Muscle weakness and fatigue
Respiratory depression — especially when combined with opioids or alcohol (FDA Boxed Warning)
Physical dependence and withdrawal syndrome (including seizures on abrupt discontinuation)
Complex sleep behaviors (sleep-driving, preparing food, making calls while not fully conscious)
Falls and hip fractures (particularly in elderly patients)
Paradoxical agitation or aggression
Severe allergic reaction/angioedema
Know what you need? Skip the search.
Temazepam (Restoril)
Most pharmacologically similar alternative — intermediate-acting benzodiazepine (8–20 hr half-life); Schedule IV; widely available; 15–30 mg at bedtime
Zolpidem (Ambien)
Most widely prescribed sleep medication; non-benzodiazepine GABA agonist; shorter-acting; Schedule IV; 5–10 mg IR or 6.25–12.5 mg ER at bedtime; very widely stocked
Eszopiclone (Lunesta)
Non-benzodiazepine hypnotic; Schedule IV; no labeled duration restriction; 1–3 mg at bedtime; generic available
Suvorexant (Belsomra)
Dual orexin receptor antagonist; different mechanism with lower dependence risk; Schedule IV; 10–20 mg; brand only
Low-dose Doxepin (Silenor)
Histamine H1 antagonist; not a controlled substance; 3–6 mg at bedtime; FDA-approved for sleep maintenance insomnia; no withdrawal risk
Prefer Flurazepam? We can find it.
Opioids (oxycodone, morphine, fentanyl, codeine)
majorFDA Boxed Warning — risk of respiratory depression, profound sedation, coma, and death when combined with flurazepam.
Alcohol
majorAdditive CNS depression; dangerous interaction continues for days after stopping flurazepam due to long-acting metabolite.
Sodium oxybate / GHB (Xyrem)
majorAbsolute contraindication — can cause life-threatening CNS and respiratory depression.
Buprenorphine (Suboxone)
majorSignificantly increased risk of respiratory depression, coma, and death. Avoid combination.
Other benzodiazepines
majorAdditive CNS depression; concurrent use not recommended.
CYP3A4 inhibitors (ketoconazole, ritonavir, mifepristone)
moderateIncrease flurazepam plasma levels; may require dose reduction and increased monitoring.
CYP3A4 inducers (carbamazepine, rifampin, phenobarbital)
moderateDecrease flurazepam effectiveness by speeding up its metabolism.
Antihistamines (diphenhydramine, cetirizine)
moderateAdditive sedation; avoid OTC sleep aids and allergy medications while on flurazepam.
Tricyclic antidepressants
moderateAdditive CNS depression; dose adjustments may be needed.
Flurazepam is a well-established benzodiazepine hypnotic that has been part of the insomnia treatment toolkit since 1968. Its long-acting profile makes it uniquely suited for patients who struggle with sleep maintenance — waking up in the middle of the night or early morning — but this same property means it carries a higher burden of next-day sedation and accumulation than shorter-acting alternatives. It is best used short-term, at the lowest effective dose, with careful attention to fall risk in elderly patients.
The supply situation in 2026 remains challenging. With only Chartwell Rx manufacturing flurazepam in the United States and distribution uneven across pharmacy networks, patients may face real difficulty filling their prescriptions. Planning ahead, trying independent pharmacies, and being aware of the ASHP shortage bulletin are all important strategies. If flurazepam is truly inaccessible, temazepam and zolpidem are widely available alternatives worth discussing with your prescriber.
If you're having trouble finding flurazepam at your local pharmacy, medfinder can help. Provide your medication, dosage, and location and medfinder will call pharmacies near you to identify which ones can fill your prescription, texting you the results. Never stop flurazepam abruptly — always work with your prescriber to ensure a safe plan for obtaining or transitioning your medication.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards